{"organizations": [], "uuid": "23450f247759ffc4b936f12037192aa6ebafa885", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-neotract-announces-fda-clearance-o/brief-neotract-announces-fda-clearance-of-expanded-indications-for-urolift-system-idUSFWN1QA02K", "country": "US", "domain_rank": 408, "title": "BRIEF-Neotract Announces FDA Clearance Of Expanded Indications For Urolift System", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.991, "site_type": "news", "published": "2018-02-20T19:43:00.000+02:00", "replies_count": 0, "uuid": "23450f247759ffc4b936f12037192aa6ebafa885"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-neotract-announces-fda-clearance-o/brief-neotract-announces-fda-clearance-of-expanded-indications-for-urolift-system-idUSFWN1QA02K", "ord_in_thread": 0, "title": "BRIEF-Neotract Announces FDA Clearance Of Expanded Indications For Urolift System", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "teleflex inc", "sentiment": "negative"}, {"name": "fda clearance of expanded indications for urolift system feb", "sentiment": "negative"}, {"name": "ift", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - Teleflex Inc:\n* NEOTRACT ANNOUNCES FDA CLEARANCE OF EXPANDED INDICATIONS FOR UROLIFTÂ® SYSTEM\n* NEOTRACT - EXPANDED INDICATIONS MEAN PATIENTS WITH OBSTRUCTIVE MEDIAN LOBE, AS YOUNG AS 45 NOW ELIGIBLE TO GET TREATMENT WITH UROLIFT FOR BPH SYMPTOMS Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-20T19:43:00.000+02:00", "crawled": "2018-02-21T21:30:38.000+02:00", "highlightTitle": ""}